chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A 21 year old female patient (JC) experienced injection site pain, nausea, vomiting and headache after receiving RabAvert for prophylactic vaccination and inoculation against rabies. Medical history and concomitant medications remained unknown. The patient received one dose of Imovax rabies vaccine on 06/10/04, intramuscularly in the right arm. One week later she received RabAvert on 06/17/04 at 11:00, one ml intramuscularly in the left arm. One hour later, she experienced a headache, injection site soreness and nausea, which proceeded to vomiting. She treated the headache with oral Ibuprofen. The headache, nausea and vomiting were all resolved by 10:00 PM that same evening, the injection site pain was resolved on 06/19/04. The patient was scheduled to continue the vaccine series on 06/10/04.
SHORTLY AFTER GETTING THE VACCINE, MY CYCLES COMPLETELY STOPPED. I ENDED UP HAVING TO CONTACT MY OBGYN AND BEING PUT ON PROVERA TO START MY CYCLE.
QUADRACEL was administered to a patient who was supposed to be given a high dose influenza vaccine with no reported adverse event; Initial information received on 20-Oct-2023 regarding an unsolicited valid non-serious case received from other health professional.  This case involves a 69 years old female patient who was administered Diphtheria-15/Tetanus/5 Hybrid AC Pertussis/IPV (MRC5) vaccine [Quadracel] was administered to a patient who was supposed to be given a high dose influenza vaccine with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 20-Oct-2023, the patient received 0.5 ml dose (frequency: once; strength: standard) of suspect Diphtheria-15/Tetanus/5 Hybrid AC Pertussis/IPV (MRC5) vaccine Suspension for injection of lot U7526AA and expiry: 07-Sep-2024 via intramuscular route in the left deltoid for immunization; who was supposed to be given a high dose influenza vaccine with no reported adverse event (wrong product administered) (latency: same day).  No lab data was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive and Regulatory Authority Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Herpes Zoster; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a currently 75-year-old male patient. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On or about 23-OCT-2014, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dose, dose# and route not specified) by a pharmacist at the pharmacy for the long-term prevention of shingles and zoster-related conditions. On an unspecified date, the patient was treated by a healthcare provider for the following injuries resulting from the use of zoster vaccine live (ZOSTAVAX): herpes zoster. The outcome of herpes zoster was not reported. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).
Information has been received from a consumer and a school nurse concerning 41 child patients who in approximately 1995 were each vaccinated with a dose of varicella virus vaccine live. In approximately 2003, the patients developed mild cases of chickenpox. Most of the children were in the first grade and had been vaccinated at their private pediatrician's offices in the area. The reporter noted that her elementary school was the only one out of six in the area that has experienced a chickenpox outbreak. The reporter notified the elementary school parents of the outbreak. Follow-up information from the nurse indicated that 13 of the reported 41 patients were not previously vaccinated with a dose of varicella virus vaccine live and all of the cases of chickenpox have recovered. One of the previously vaccinated patients was a 7 year old patient (Grade 03 1M) who on 25-Feb-1997 was vaccinated with a dose of varicella virus vaccine live. On 26-Feb-2003, the patient developed chickenpox. The previously vaccinated patients included two siblings in elementary school who were vaccinated by the same pediatrician and subsequently developed mild outbreaks of chickenpox. The other patients that developed chickenpox post vaccination with varicella virus vaccine live were also identified (WAES #0305USA00974, 0306USA00276, 0306USA00277, 0309USA01822 through 0309USA01826 and 0309USA01828 through 0309USA01846). Additional information is not expected.
Post vax 4th Anthrax, pt developed new symptoms of tunnel vision and light-headedness. Also, had similar symptoms of myalgias and malaise as with previous Anthrax vaccinations.
Initially she felt reddness, warmth, and blotchy around injection site that spread to other arm. She also developed red spots on multiple areas of her bodyassociated with pustules but no vesicles. she also had a fever for 2 1/2 days.
This spontaneous report as received from a pharmacist refers to a patient of unknown age, who on 10-AUG-2012 was vaccinated with a dose of PNEUMOVAX23 (lot # 669380/1397Z) (dose and route not reported) that expired on 04-AUG-2012. The patient was not experienced any known symptoms. No treatment information was reported. Additional information has been requested.
Pt broke out with raised, blistery rash on 7/10/02 following a low-grade fever. Rash mostly on trunk of body but also on extremities. Scabbing over today.
Parents reported that within 24 hours of vaccines that pt began acting strangely, including flapping arms, hitting herself, biting.
Systemic: Patient has had 3 nosebleeds lasting a few minutes each 1-2 days after vaccine given.-Mild, Additional Details: Patient came to the pharmacy and said after the second dose of pfizer vaccine on 05/03/21 the next day (5/4/21) she had a nosebleed lasting a few minutes as well as to 2 other nosebleeds on 05/05/2021 each only for a few minutes. Patient said she doesn't ever get nosebleeds but noticed that her nose was very dry. Patient said she was feeling fine and didn't need immediate treatment. She was encouraged to notify doctor of this & had talked to the pharmacist on phone about how to treat dryness.
Does not have Lot #. Left it at work. Dizzy 15 mins after. BP was high. Dizzy rest of day. Worked the next day was ok. Started driving the next day on interstate 12/25/20,  and had chest pressure. Pulled of in to a hospital their and had testing done.  Went home had dizziness still. Went to her MD, the doc changed her blood pressure meds. She doesn't have the dizziness and the chest pressure any more.  Blood pressure is still high and monitoring it a few times a day.
Information has been received from a pharmacist referring to multiple unspecified pharmacists of unknown age and gender. No relevant medical history or concurrent conditions were reported. On unknown dates these pharmacists developed shingles an unspecified amount of time after they administered ZOSTAVAX (vaccination dates, doses, frequencies, lot # and expiration dates were unknown) to unspecified patients. The reporting pharmacist stated that one of these pharmacist had ever received ZOSTAVAX and the reporting pharmacist wondered if this could be potential transmission from the vaccines. At the time of this report, the outcome of the events was unknown. Additional information has been requested.
Got some adjuvant suspension in my eye when I was preparing the arexvy dose; Adjuvant suspension in my eye; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of occupational exposure while preparing product for administration in a 33-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number Jc7z5, expiry date 01-FEB-2025) for prophylaxis.   On an unknown date, the patient did not receive Arexvy. On 20-SEP-2023, an unknown time after receiving Arexvy, the patient experienced occupational exposure while preparing product for administration (Verbatim: Got some adjuvant suspension in my eye when I was preparing the arexvy dose) and exposure via eye contact (Verbatim: Adjuvant suspension in my eye).  The outcome of the occupational exposure while preparing product for administration and exposure via eye contact were unknown.   Additional Information: GSK Receipt Date: 20-SEP-2023 The reporter reported that he got some adjuvant suspension his eye when he was preparing the arexvy vaccine dose, which led to occupational exposure while preparing product for administration and exposure via eye contact. The reporter wanted to know what he need to do and as of did not sting or cause any sort of reaction so far. The reporter consented to follow up.
First Dose: 2-3 hours later -> extremely tired, pain in the left arm for 1.5 days, could not raise arm 3-4 days later -> eczema (rash, itchy, red, bumpy)on the right leg & right arm. The itching stopped 10 days later after the vaccine,  the redness took ~ 7 days to go away after the itching went away.  Patient evaluated severity as mild to moderate Second Dose: Pain in the arm again 1.5 days, 25 hours after the vaccine suddenly very tired (took 2 hour nap, was ok after that), felt cold when was taking a nap
8 days post vaccine developed Shingles on right front chest. Of note: 1 day post vaccine developed fever over 101F, swelling in right arm, very enlarged lymph nodes in right armpit. Fever broke after 1 day, arm pain lasted 4 days, swollen lymph nodes began to lessen after 1 week, still slightly enlarged two weeks later.
Pt received a varicella vaccine on 6-6-07, reports a headache and a sore arm the 1 st day after the vaccine, on day 2 pt reported arm swelling, redness, pain and limited range of motion in her left arm. Pt was seen at  Health Center for treatment on 6-08-07, pt was given a prescription for Benadryl and the redness on her arm was recorded, pt instructed to go to the ER if reddened area enlarges overnight. Pt went to the Medical Center on 6-8-07. Pt returned to Health Center for a follow up on 6-9-07 and reaction had resolved.
Information has been received from a health professional concerning a 2 year old female with no known medical history or allergies who on 20-SEP-2004 was vaccinated in the thigh with a 0.5ml first dose of varicella virus vaccine live (Oka/Merck) (lot #648551/0283P). There was no concomitant medication. On 03-JAN-2006 the patient developed chickenpox. She had multiple lesions on her back and thighs. Unspecified medical attention was sought. There were no laboratory diagnostic tests performed. At the time of the report the patient had recovered. There was no product quality complaint involved. Additional information has been requested.
Lips blistered and swollen, continuing to today. Allergic reaction to tree pollen. Some difficulty breathing when outdoors and high pollen counts.
WITH IN ONE MINUTE , BURNING PAIN  IN LEFT ARM STARTING AT INJECTION SITE SPREADING DOWN ARM, WITHIN 25 MINUTES  TONGUE,AND LIPS STARTED TO ITCH.  WITHIN 40 MINUTES  ITCHY  RASH ON FACE . THEN WITHIN ONE HOUR IT  SPREAD TO HEAD NECK AND STOMACH.  TOOK BENADRYL 25 MG  EASED OFF RASH  AND ITCHING.  STILL TAKING BENADRYL  .TO  REDUCE RASH AND ITCHING
Receive first dose vaccine 12/18/20. On 12/24/20 awakened with vertigo/nausea/vomitting.  Self treated (as had similar 4 years earlier)  with Epley maneuver, rest.    Symptoms gradually improved over 2 dayes. Received 2nd dose 1/8/21.  Awakened early 1/12/21 with vertigo, nausea, vomitting.  Again it is improving with self treatment but contacted UConn vaccine call center who suggested I file this.
Painful headache all Friday morning until afternoon.  Body ache all morning and day Friday.  Took Tylenol three times Friday.
Severe diarrhea; Hot flashes; Sinus pressure; Migraines; Chills; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Severe diarrhea), HOT FLUSH (Hot flashes), PARANASAL SINUS DISCOMFORT (Sinus pressure), MIGRAINE (Migraines) and CHILLS (Chills) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In March 2021, the patient experienced DIARRHOEA (Severe diarrhea), HOT FLUSH (Hot flashes), PARANASAL SINUS DISCOMFORT (Sinus pressure), MIGRAINE (Migraines) and CHILLS (Chills). At the time of the report, DIARRHOEA (Severe diarrhea), HOT FLUSH (Hot flashes), PARANASAL SINUS DISCOMFORT (Sinus pressure), MIGRAINE (Migraines) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication provided. No treatment information mentioned.
Developed swelling/fever, tenderness in this area. Diagnosed with Cellulitis. Hospitalized for 3 days (left buttocks). 11/18/05 D/C summary review confirms diagnosis of cellulitis with redness and inflammation of L buttock.
10:10 am received Moderna vaccine; observation time 30 min due to previous allergies stated (shrimp-throat closure); 10:37 am  RN was observing/talking to pt & mid-sentence pt. reported "I'm feeling funny." Resident's eyes appeared glazed over and she reported "feeing out of it. Like I'm in another world." Resident unable to provide any further specific descriptions of how she felt. Resident's radial pulse felt regular. No loss of consciousness. Resident remained in seated position. 10:39 am Resident reported no improvement & stated, "I feel week".  Rn paged for assistance. 10:45 am another staff member arrived with bp cuff. L upper arm blood pressure was 136/72. Heart rate remains regular. Lungs sounded clear. Resident was able to drink a 1/2 glass of orange juice. 10:49 Resident reported feeling " a little better." 10:51 am  We noted resident's face appeared flush. No baseline observation of what her cheeks looked like prior to vaccination due to mask, but questionable mild facial swelling present. 10:53 asked resident if she was able to swallow normally. Resident wasn't sure, so RN asked if she felt like she had a lump in her throat or like she needed to clear her throat, but couldn't and she confirmed that her throat felt different than normal. 10:55 am Epi pen administered to L outer thigh by RN. Call placed to EMS. Discussed expected side effects of Epi administration. 10:57 am Resident started to feel anxious and visible shaking present. 11:05 am Resident reported felling slightly better, perked up a bit. 11:08am EMS arrived. 11:10 Ambulance crew arrived. Resident was able to walk to stretcher with assist of 1. 11:17 am Ambulance left with resident. Resident was still reporting "feeling weak".
Pt recv vax on 11/4/98; on 11/25/98 pt exp sore left deltoid muscle
Swollen and painful armpit lymph node. Swoll up about 5 days after shot and is still swollen and painful to touch.
shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. Information on the patient's concurrent conditions, medical history or concomitant therapy was not reported.    On an unknown date in 2015, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, lot# and expiration date were not reported) for long-term prevention of shingles and zoster-related conditions. On an unknown date, the patient was treated by healthcare provider for the following injuries resulting from zoster vaccine live (ZOSTAVAX) use: shingles. The outcome of shingles was unknown.   Additional information has been requested.
An investigator reported that an unidentified pt received Prevnar and MMR vaccines on 05/01/2002, as part of a study. During 04/09/2002 to 05/09/2002, at week 16 of the study, the pt developed erythema that was graded 3. According to protocol, grade 3 reactions were considered serious adverse events. The investigator assessed the erythema as definitely related to Prevnar vaccine administration. The medical monitor assessment is unknown.
A phone call was made to the patient a couple days after her second vaccination and she reported that she had experienced fatigue and headache starting the night of her vaccination.
This case was reported by a physician, via a GSK representative, and described the occurrence of diarrhea in approximately 5 to 10 infant subjects of unspecified gender who were vaccinated with ROTARIX (GlaxoSmithKline). On an unspecified date the subjects received 1st dose of ROTARIX (details unknown). At an unspecified time after vaccination with ROTARIX, the subjects experienced diarrhea. At the time of reporting the event was resolved. The physician reported that diarrhea had been observed in several (approximately 5 to 10) subjects following the 1st dose of ROTARIX (this case). One infant had been hospitalized for dehydration due to severe diarrhea (see case ID A0951277A).
Patient was giving a second dose of moderna at about 3:45 pm and at 3:51pm patient started to develop fatigue and weakness sysmptoms. Suddenly patient started complaining about dry mouth and dizziness and he was not able to  stand on his feet.  He tried to stand up and he faint on the chair. I layed him down flat on a table and squeezed his legs allowing the blood flow towards his head (brain). Patient started to feel better but, suddenly started having shortness of breath. At that moment, I called for emergency help. patient was awake and concious all the time.
inadvertantly administered a dose of Proquad instead of MMRII; no adverse effect; This spontaneous report was received from a nurse regarding a 16-year-old patient gender was not reported. The patient's medical history, concurrent condition and concomitant medications were not reported. The nurse described that two siblings, both sixteen years old, were inadvertently vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD), therapy type rHa, lot # S002496 and expiry date 23-JUL-2020, (strength, dose, route were not reported) for prophylaxis, instead of measles, mumps, and rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (wrong product administered). No adverse effects reported.   This is one of several reports received from the same reporter.
After the second shot of Moderna COVID-19 Vaccine, more severe rash appeared on his arms and legs; This spontaneous case was reported by a consumer and describes the occurrence of RASH (After the second shot of Moderna COVID-19 Vaccine, more severe rash appeared on his arms and legs) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunization.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced RASH (After the second shot of Moderna COVID-19 Vaccine, more severe rash appeared on his arms and legs). At the time of the report, RASH (After the second shot of Moderna COVID-19 Vaccine, more severe rash appeared on his arms and legs) had resolved.            No concomitant medication information was provided.  It was reported that the patient had more severe rash that appeared on his arms and legs which took 2-3 weeks to go away.  No treatment information was provided.   This case was linked to MOD-2022-653596, MOD-2022-653582 (Patient Link).   Reporter did not allow further contact
patient claims she developed a rash all over the body starting the day after the injection. the rash lasted several days (1/16 to 1/22 2020).
Information has been received from a woman in a physician's office concerning a 19 month old white male with no allergies or medical history who on 01-NOV-2005 was vaccinated in the left arm with a dose of Varivax (lot # 646536/0550R). There was no illness at the time of vaccination. On an unspecified date, the patient developed chickenpox and subsequently recovered. Additional information has been requested.
It's like I'm smelling like an ammonia-like compound / change in my sense of smell, not loss; my nose is irritated; annoying and itching; sneezing, its been intermittant, worse in the evening; feels burning in his eyes; This spontaneous case was reported by a consumer and describes the occurrence of PAROSMIA (It's like I'm smelling like an ammonia-like compound / change in my sense of smell, not loss), NASAL DRYNESS (my nose is irritated), PRURITUS (annoying and itching), SNEEZING (sneezing, its been intermittant, worse in the evening) and EYE IRRITATION (feels burning in his eyes) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy (around this time of year).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAROSMIA (It's like I'm smelling like an ammonia-like compound / change in my sense of smell, not loss), NASAL DRYNESS (my nose is irritated), PRURITUS (annoying and itching), SNEEZING (sneezing, its been intermittant, worse in the evening) and EYE IRRITATION (feels burning in his eyes). At the time of the report, PAROSMIA (It's like I'm smelling like an ammonia-like compound / change in my sense of smell, not loss), NASAL DRYNESS (my nose is irritated), PRURITUS (annoying and itching), SNEEZING (sneezing, its been intermittant, worse in the evening) and EYE IRRITATION (feels burning in his eyes) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2021: Patient's contact details were updated. He declined further FU.
Less than 24 hours after receiving 2nd dose of vaccine, resident developed symptoms of fever (101.7F), body aches, peri-orbital fluid in right eye, right eyelid ptosis with mild facial droop, tongue deviates to the right.
After the first dose for the Pfizer, I experienced a metal like taste in mouth, shortly after. However, that went away within an hour. I had the typical low side effects of localized injection soreness, swelling, redness, warmth feeling and it was red around the injection site. The following two days after vaccination (2/22/21) I experienced the expected low side effects. On the third day after vaccination, I was feeling well again.   However, yesterday 3/2/21, I noticed the area where I received the Covid vaccine was red again, with itching, warmth feeling, redness, and a bit of burning sensation. This is only apparent on the injection site. I contacted the CDC today, 3/3/21 and they directed me to you to report this and also to contact my healthcare provider, which I have. The CDC was not able to tell me if it was considered normal to have the localized injection site side effects resurface again a week after receiving the 1st dose vaccine.   Therefore, I was advised by the CDC to report it. It is also unclear to me if the reason for the localized injection site side-effects being more prominent because of where the injection was administered. There is a question about it having been administered closer to subcutaneously by the nurse than intramuscular, but I do not know.